Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | ITK | Q08881 | 9/20 | 0.48 |
| ▸ | BTK | Q06187 | 4/20 | 0.43 |
| ▸ | TEC | P42680 | 2/20 | 0.43 |
| ▸ | TXK | P42681 | 2/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17121819 | 1.00 | EGFR (0.60) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL17121731 | 1.00 | EGFR (0.60) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL22434276 | 0.92 | EGFR (0.59) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL18681756 | 0.90 | EGFR (0.60) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL19037502 | 0.90 | EGFR (0.60) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL29895878 | 0.90 | EGFR (0.60) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL17121630 | 0.90 | EGFR (0.57) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL19037550 | 0.89 | EGFR (0.66) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL20305968 | 0.89 | EGFR (0.66) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL17121732 | 0.89 | EGFR (0.55) | EGFRCYP2D6CYP3A4CYP2C9ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989140-B | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | 卡佩拉医疗公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20250092028-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| CN-114940673-B | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | 卡佩拉医疗公司 | 2025-03-18 | — | — | CN | disclosed |
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CAPELLA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| CN-114989140-A | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | 卡佩拉医疗公司 | 2022-09-02 | — | — | CN | disclosed |
| US-11427565-B2 | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | CAPELLA THERAPEUTICS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| CN-114940673-A | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | 卡佩拉医疗公司 | 2022-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CCNI, CYP2C19, PHB1 | EGFR 2304/4885CYP2D6 52/4885CYP3A4 15/4885 |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CHKB, CHKA, CHUK | EGFR 1973/4885CYP2D6 1914/4885CYP3A4 636/4885 |
| US-20250092028-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | EGFR 4/4885CYP2D6 1898/4885CYP3A4 1537/4885 |
| US-11427565-B2 | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | CHKB, CHKA, CHUK | EGFR 1973/4885CYP2D6 1914/4885CYP3A4 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.